Lavipharm S.A risk profile
35 Normal where most of the sector sits
Measured 21 October 2026 from LAVI's filed statements. Recomputed nightly.
35 (Normal), driven by Cash conversion at 52, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 44 | Elevated | Stable | One-year price volatility — 41.1% |
| Operating pressure | 26 | Normal | Easing | Operating-margin drift — +4.8 percentage points |
| Cash conversion | 52 | Elevated | Easing | Capital spending against operating cash — 0.69x |
| Leverage and coverage | 36 | Normal | Easing | Current ratio — 1.21x |
| Competitive position | 34 | Normal | Stable | R&D-intensity gap against peers — -28.1 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.